Hold Metropolis Healthcare; target of Rs 1440: ICICI Securities
ICICI Securities recommended hold rating on Metropolis Healthcare with a target price of Rs 1440 in its research report dated August 04, 2023.09-08-2023
09-08-2023
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
This is in continuation to our letter bearing reference No: MHL/Sec & Legal/2023-24/37 dated July 29, 2023, with respect to the intimation of Conference Call for the quarter ended June 30, 2023, and pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 the audio recording of the Conference call held today i.e August 03, 2023, at 9:00 a.m. (IST) to discuss the Q1FY24 Financial Results of the Company is available on the Company's website under the below link: https://www.metropolisindia.com/newdata/Investors/Submission-to-Stock-Exchange/2023-24/Q2/Metropolis%20Q1FY24%20Earnings%20Call%20Audio.mp303-08-2023
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Newspaper Publication
This is to inform you that the Company on Thursday, August 03, 2023 has published an extract of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2023 as approved by the Board of Directors in their Meeting held on Wednesday, August 02, 2023. Please find enclosed, the copy published in Free Press Journal (English) and Navshakti (Marathi).03-08-2023
Metropolis Healthcare Results Earnings Call for Q1FY24
Conference Call with Metropolis Healthcare Ltd. Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.03-08-2023
Q1FY24 Quarterly Result Announced for Metropolis Healthcare Ltd.
Metropolis Healthcare announced Q1FY24 results: Core business revenue growth stood at Rs 271 crore, up 12% YoY with 9% volume growth & 3% RPT growth Core business patients stood at 2.7 million with a growth of 9% YoY Total B2C revenue in grew by 13% for Q1FY24 YoY with volume growth of 9% EBIDTA before network expansion stood at 25.3% Premium wellness segments revenue grew by 27% & volumes grew by 38% indicating strong brand equity & consumer trust on Metropolis. Contribution of premium wellness stood at 15% B2C revenue growth in Mumbai stood at 15% on account of our strong brand presence & dense network “In Q1FY24, the core business revenues grew by 12% YoY, reflecting a consistent trend of double-digit growth over the past five quarters for its core revenues. Total Revenues for Q1FY24 were down by 1% primarily on account of a large B2G contract insourced by the Government & a high base of Covid & Allied tests. The company remains optimistic about scaling up revenue in the upcoming quarters, indicating positive operating leverage play. B2C revenue grew by 13% YoY with Mumbai revenues for B2C growing by over 15%. Metropolis has witnessed growth across the test mix in B2C markets with Specialised and Wellness segments growing by 15% & 19% respectively on a YoY basis. Going forward, the company focuses on network expansion, increasing doctor connections, growing specialised & wellness segments, and upgrading IT infrastructure to enhance the consumer experience. We firmly believe that Metropolis is in an advantageous position to achieve a higher market share across various geographies and surpass industry growth", said Ameera Shah, Promoter and Managing Director, Metropolis Healthcare. Result PDF03-08-2023
Metropolis Healthcare edges up despite 13.8% decline in Q1 net profit
Revenues from core business grew by 12% on a year-on-year basis to Rs 271 crore.03-08-2023
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of SEBI(LODR), regulations, 2015, enclosed herewith is the press release as mentioned below: "Metropolis'' Core-Revenue Growth (Excl. Covid & Covid allied, PPP contract) at Rs. 271 Crs in Q1FY24; up by 12% YoY"02-08-2023
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of SEBI (LODR) regulations, 2015, we are enclosing herewith Investor Presentation for the quarter ended June 30, 202302-08-2023
Metropolis Healthcare Ltd - 542650 - Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting Held On Wednesday, August 02, 2023
This is to inform you that, the Board of Directors of the Company in their meeting held today i.e August 02, 2023, have inter alia approved few agendas, details of which are enclosed herewith.02-08-2023
Metropolis Healthcare Ltd - 542650 - Unaudited Financial Results (Standalone And Consolidated) For Quarter Ended June 30, 2023
Please find attached herewith, Unaudited Financial results (standalone and consolidated) for quarter ended June 30, 202302-08-2023